Compare MLYS & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | VINP |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 807.6M |
| IPO Year | 2023 | 2021 |
| Metric | MLYS | VINP |
|---|---|---|
| Price | $37.20 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $47.33 | $13.50 |
| AVG Volume (30 Days) | ★ 1.5M | 44.3K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | ★ 4.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $180,689,571.00 |
| Revenue This Year | N/A | $67.12 |
| Revenue Next Year | N/A | $15.14 |
| P/E Ratio | ★ N/A | $26.15 |
| Revenue Growth | N/A | ★ 100.47 |
| 52 Week Low | $8.24 | $8.66 |
| 52 Week High | $47.65 | $13.37 |
| Indicator | MLYS | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 65.49 |
| Support Level | $36.50 | $12.77 |
| Resistance Level | $38.23 | $13.37 |
| Average True Range (ATR) | 1.68 | 0.29 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 41.96 | 80.95 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.